{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:10:07Z","timestamp":1759147807314,"version":"3.44.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40262-025-01556-7","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T09:22:13Z","timestamp":1754731333000},"page":"1575-1585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug\u2013Drug Interactions Between Direct Oral Anticoagulants and Other Medications in Patients with Pulmonary Embolism: Results from the Lungenembolie Augsburg (LEA)"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-2659","authenticated-orcid":false,"given":"Klaus Peter","family":"Schmelzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Freuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Berghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Linseisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Meisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger K, Moerchel C, Moysidis Th, Santosa Frans, Incidence rate of pulmonary embolism in Germany: Data from the Federal Statistical Office. Journal of Thrombosis and thrombolysis, 29(3):349-53.","DOI":"10.1007\/s11239-009-0396-1"},{"key":"1556_CR2","unstructured":"Wilkens, Heinrike, Held, Matthias Lungenembolie: Status 2018. Dtsch Arztebl Int 2021; 118: 618-2."},{"issue":"6","key":"1556_CR3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","volume":"158","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585\u201393.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1556_CR4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","volume":"5","author":"IA Naess","year":"2007","unstructured":"Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstr\u00f8m J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692\u20139.","journal-title":"J Thromb Haemost"},{"key":"1556_CR5","doi-asserted-by":"crossref","unstructured":"Hojen AA, Nielsen PB, Overvad TF, Albertsen IE, Klok FA, Rolving N, et al. Long-term management of pulmonary embolism: a review of consequences, treatment, and rehabilitation. J Clin Med. 2022;11(19):5970.","DOI":"10.3390\/jcm11195970"},{"issue":"10","key":"1556_CR6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095\u2013106.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1556_CR7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","volume":"31","author":"E Nutescu","year":"2011","unstructured":"Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326\u201343.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"1556_CR8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40266-022-01001-5","volume":"40","author":"JE Hughes","year":"2023","unstructured":"Hughes JE, Waldron C, Bennett KE, Cahir C. Prevalence of drug-drug interactions in older community-dwelling individuals: a systematic review and meta-analysis. Drugs Aging. 2023;40(2):117\u201334.","journal-title":"Drugs Aging"},{"key":"1556_CR9","doi-asserted-by":"crossref","unstructured":"Carollo M, Crisafulli S, Vitturi G, Besco M, Hinek D, Sartorio A, et al. Clinical impact of medication review and deprescribing in older inpatients: a systematic review and meta-analysis. J Am Geriatr Soc. 2024.:1-8","DOI":"10.1111\/jgs.19035"},{"key":"1556_CR10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","volume":"11","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967\u201377.","journal-title":"Ther Clin Risk Manag"},{"key":"1556_CR11","doi-asserted-by":"crossref","unstructured":"Egholm G, Olesen JS, Lein\u00f8e EB, Grove EL, Nielsen JD, Poulsen MH. Anticoagulation therapy for complex patient populations. Ugeskr Laeger. 2024;186(42):1-8.","DOI":"10.61409\/V05240367"},{"issue":"11","key":"1556_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.36290\/vnl.2018.146","volume":"64","author":"D Karetov\u00e1","year":"2018","unstructured":"Karetov\u00e1 D, Bultas J. Anticoagulant therapy in the elderly. Vnitr Lek. 2018;64(11):1011\u201320.","journal-title":"Vnitr Lek"},{"key":"1556_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.thromres.2024.05.006","volume":"238","author":"A Capiau","year":"2024","unstructured":"Capiau A, Mehuys E, Grymonprez M, Van Tongelen I, Christiaens T, Tommelein E, et al. Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants: an intervention study in community pharmacies. Thromb Res. 2024;238:223\u201331.","journal-title":"Thromb Res"},{"issue":"10","key":"1556_CR14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031411","volume":"9","author":"C Meisinger","year":"2019","unstructured":"Meisinger C, Linseisen J, Kirchberger I, von Scheidt W, Berghaus TM. Long-term outcomes in patients with acute pulmonary embolism after in-hospital treatment: study protocol of the prospective Lungenembolie Augsburg Studie (LEA study). BMJ Open. 2019;9(10): e031411.","journal-title":"BMJ Open"},{"issue":"6","key":"1556_CR15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.thromres.2015.03.031","volume":"135","author":"PM Frey","year":"2015","unstructured":"Frey PM, M\u00e9an M, Limacher A, Leiss W, Schwab N, Rochat M, et al. Quality of life after pulmonary embolism: prospective validation of the German version of the PEmb-QoL questionnaire. Thromb Res. 2015;135(6):1087\u201392.","journal-title":"Thromb Res"},{"issue":"5","key":"1556_CR16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1197\/jamia.M1296","volume":"11","author":"P Martin","year":"2004","unstructured":"Martin P, Haefeli WE, Martin-Facklam M. A drug database model as a central element for computer-supported dose adjustment within a CPOE system. J Am Med Inform Assoc. 2004;11(5):427\u201332.","journal-title":"J Am Med Inform Assoc"},{"key":"1556_CR17","first-page":"906","volume":"270","author":"O Olakotan","year":"2020","unstructured":"Olakotan O, Mohd Yusof M, Ezat Wan Puteh S. A systematic review on CDSS alert appropriateness. Stud Health Technol Inform. 2020;270:906\u201310.","journal-title":"Stud Health Technol Inform."},{"key":"1556_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41746-020-0221-y","volume":"3","author":"RT Sutton","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020;3:17.","journal-title":"NPJ Digit Med."},{"issue":"3","key":"1556_CR19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/ejhpharm-2014-000561","volume":"22","author":"A Pauly","year":"2015","unstructured":"Pauly A, Wolf C, Busse M, Strau\u00df A-C, Krebs S, D\u00f6rje F, et al. Evaluation of eight drug interaction databases commonly used in the German healthcare system. Eur J Hosp Pharm. 2015;22(3):165\u201370.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"1556_CR20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10278-019-00219-x","volume":"33","author":"A Elovic","year":"2020","unstructured":"Elovic A, Pourmand A. Lexicomp app review. J Digit Imaging. 2020;33(1):17\u201320.","journal-title":"J Digit Imaging"},{"key":"1556_CR21","unstructured":"AWMF. S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und Lungenembolie: Deutsche Gesellschaft f\u00fcr Angiologie - Gesellschaft f\u00fcr Gef\u00e4\u00dfmedizin e.V. (DGA); 2023 [medical guideline]. Available from: https:\/\/www.awmf.org\/fachgesellschaften\/deutsche-gesellschaft-fuer-angiologie-gesellschaft-fuer-gefaessmedizin-e-v-dga. [accessed 12.Dez 2024]"},{"issue":"21","key":"1556_CR22","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395.","journal-title":"Circulation"},{"issue":"6","key":"1556_CR23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","volume":"105","author":"J Niu","year":"2019","unstructured":"Niu J, Straubinger RM, Mager DE. Pharmacodynamic Drug-drug interactions. Clin Pharmacol Ther. 2019;105(6):1395\u2013406.","journal-title":"Clin Pharmacol Ther"},{"key":"1556_CR24","unstructured":"Prescribing information Eliquis US Pfizer Inc. 2012 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf.] [accessed 22 Nov 2024]"},{"key":"1556_CR25","unstructured":"Product Monograph Eliquis Pfizer Inc. Canada 2011 [updated 07.10.2019. Product Monograph]. Available from: https:\/\/webfiles.pfizer.com\/file\/89048fb0-de12-4e0d-b6fe-d1351e77108b?referrer=ccb731e5-4f2d-4f4a-b2dc-e5e912145fc6. [accessed 18 Nov 2024]"},{"key":"1556_CR26","unstructured":"Company B-MS. Medication Guide Eliquis Apixaban 2015 [Available from: https:\/\/www.fda.gov\/media\/84985\/download.] [accessed 21 Nov 2024]"},{"issue":"11","key":"1556_CR27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"8","key":"1556_CR28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"9683","key":"1556_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"issue":"6","key":"1556_CR30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamainternmed.2014.946","volume":"174","author":"BL Davidson","year":"2014","unstructured":"Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014;174(6):947\u201353.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"1556_CR31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14779072.2018.1521721","volume":"16","author":"A Clarke","year":"2018","unstructured":"Clarke A, Ibrahim A, Kiernan TJ. Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice. Expert Rev Cardiovasc Ther. 2018;16(10):715\u201323.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"1556_CR32","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/bcp.14277","volume":"86","author":"G Mikus","year":"2020","unstructured":"Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol. 2020;86(8):1632\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1556_CR33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40262-024-01350-x","volume":"63","author":"BS Rohr","year":"2024","unstructured":"Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, et al. Time course of the interaction between oral short-term ritonavir therapy with three factor Xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers. Clin Pharmacokinet. 2024;63(4):469\u201381.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1556_CR34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40262-021-01051-9","volume":"61","author":"BS Rohr","year":"2022","unstructured":"Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, et al. Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as a microdosed cocktail. Clin Pharmacokinet. 2022;61(1):97\u2013109.","journal-title":"Clin Pharmacokinet"},{"key":"1556_CR35","unstructured":"Product Monograph Rivaroxaban Xarelto Canada 2018 [Available from: https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=92592.] [accessed 10.11.2024]"},{"key":"1556_CR36","unstructured":"Prescribing Information Xarelto Janssen Pharmaceuticals Inc US 2015 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022406s012lbl.pdf.] [accessed 20 Oct 2024]"},{"issue":"9","key":"1556_CR37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","volume":"46","author":"D Kubitza","year":"2006","unstructured":"Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban\u2013an oral, direct factor Xa inhibitor\u2013are not affected by aspirin. J Clin Pharmacol. 2006;46(9):981\u201390.","journal-title":"J Clin Pharmacol"},{"issue":"52","key":"1556_CR38","first-page":"A6568","volume":"157","author":"AJ Risselada","year":"2013","unstructured":"Risselada AJ, Visser MJ, van Roon E. Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd. 2013;157(52):A6568.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"10","key":"1556_CR39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjmed.2021.06.003","volume":"134","author":"AL Sennesael","year":"2021","unstructured":"Sennesael AL, Larock AS, Hainaut P, Lessire S, Hardy M, Douxfils J, et al. The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. Am J Med. 2021;134(10):1295\u20139.","journal-title":"Am J Med"},{"issue":"6","key":"1556_CR40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526\u201336.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1556_CR41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331\u201342.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"21","key":"1556_CR42","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","volume":"132","author":"SR Vazquez","year":"2018","unstructured":"Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230\u20139.","journal-title":"Blood"},{"key":"1556_CR43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","volume":"194","author":"A Li","year":"2020","unstructured":"Li A, Li MK, Crowther M, Vazquez SR. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. Thromb Res. 2020;194:240\u20135.","journal-title":"Thromb Res"},{"key":"1556_CR44","doi-asserted-by":"crossref","unstructured":"Wang Z, Li X, Zou Y, Li X, Lv Q. Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation. Ann Pharmacother. 2024 Aug;58(8):761-770","DOI":"10.1177\/10600280231211306"},{"issue":"13","key":"1556_CR45","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, et al. Association between use of non-vitamin k oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250\u20139.","journal-title":"JAMA"},{"key":"1556_CR46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biopha.2016.06.012","volume":"83","author":"PM Leite","year":"2016","unstructured":"Leite PM, Martins MAP, Castilho RO. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. Biomed Pharmacother. 2016;83:14\u201321.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1556_CR47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/17425255.2024.2322134","volume":"20","author":"M Carollo","year":"2024","unstructured":"Carollo M, Crisafulli S, Ciccimarra F, And\u00f2 G, Diemberger I, Trifir\u00f2 G. Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants. Expert Opin Drug Metab Toxicol. 2024;20(3):157\u201364.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01556-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:49:08Z","timestamp":1759146548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01556-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"23 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Klaus Peter Schmelzer, Dennis Freuer, Simone Fischer, Thomas M. Berghaus, Jakob Linseisen and Christa Meisinger declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"KPS: Conceptualization, data curation, analysis, software, investigation, methodology, project administration, resources, supervision and writing. DF: Data curation, analysis, visualization and writing. SF: Reviewing and editing. TMB: Reviewing and editing. JL: Reviewing and editing. CM: Project administration, supervision, writing, reviewing and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement:"}},{"value":"The study protocol was approved by the Ethics Committee of the Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (date of approval: 1 August 2017; reference number: 17\u2013378).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from each study participant.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}